Michael Quagliata, Silvia Bracci, Roberta Squecco, Livio Tarchi, Valdo Ricca, Anna Maria Papini, Paolo Rovero
{"title":"A patent review of GDF15 inhibitors 2020-present.","authors":"Michael Quagliata, Silvia Bracci, Roberta Squecco, Livio Tarchi, Valdo Ricca, Anna Maria Papini, Paolo Rovero","doi":"10.1080/13543776.2026.2763536","DOIUrl":"10.1080/13543776.2026.2763536","url":null,"abstract":"<p><strong>Introduction: </strong>Growth/differentiation factor 15 (GDF15) is a secretory protein of the TGF-β superfamily that signals through the GFRAL/RET receptor complex. It plays a dual role in metabolic regulation and immune tolerance, with elevated levels frequently associated with chronic inflammatory conditions, advanced cancer, and cachexia.</p><p><strong>Area covered: </strong>This review analyzes the patent landscape for GDF15 inhibitors from January 2020 to present. The patents reviewed were originally written in English and classified according to different functional categories and disease types. We searched for 'GDF15 inhibitor' on Patentscope and Espacenet.</p><p><strong>Expert opinion: </strong>Monoclonal antibodies currently dominate the landscape due to their high specificity and favorable safety profile, showing significant clinical promise in treating cancer cachexia and overcoming resistance to checkpoint inhibitors. However, challenges such as high production costs and the need for parenteral delivery and its consequences are driving a shift in the research toward simpler molecular structures. Emerging trends suggest that peptides and peptidomimetics offer a viable alternative by maintaining high selectivity while being available through cost-effective synthesis that also allows for tunable properties.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1-10"},"PeriodicalIF":4.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A patent review of anti‑VEGF antibodies for the treatment of ocular diseases (2020-present).","authors":"Georgios D Panos","doi":"10.1080/13543776.2026.2760557","DOIUrl":"https://doi.org/10.1080/13543776.2026.2760557","url":null,"abstract":"<p><strong>Introduction: </strong>Anti-VEGF therapy remains central to the management of neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion, but treatment burden and limited durability remain major unmet needs. This review examines how recent patenting has shifted from first-generation anti-VEGF binders toward approaches designed to extend intraocular durability and strengthen product differentiation.</p><p><strong>Areas covered: </strong>This article reviews the patent landscape for antibody-based VEGF inhibition in ophthalmology from 1 January 2020 to 18 September 2026. Patent databases of the World Intellectual Property Organization (WIPO), US Patent and Trademark Office (USPTO), European Patent Office (EPO), Japan Patent Office (JPO), and China National Intellectual Property Administration (CNIPA) were searched for composition-of-matter, formulation, method-of-treatment, and delivery claims. The review covers bispecific antibodies, antibody-biopolymer conjugates, gene-encoded antibody fragments, and high-concentration ophthalmic formulations, with relevant clinical programs used to provide context.</p><p><strong>Expert opinion: </strong>Anti-VEGF antibody patenting is now driven mainly by durability rather than by new binding targets alone. Over the next few years, competitive advantage is likely to depend on the successful integration of molecular format, formulation, delivery, and manufacturability into clinically reliable long-acting products.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1-18"},"PeriodicalIF":4.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rafia Ashfaq, Nilufar Z Mamadalieva, Hidayat Hussain
{"title":"Therapeutic potential of glycyrrhetinic acids: an updated patent review (2018-2024).","authors":"Rafia Ashfaq, Nilufar Z Mamadalieva, Hidayat Hussain","doi":"10.1080/13543776.2026.2759921","DOIUrl":"10.1080/13543776.2026.2759921","url":null,"abstract":"<p><strong>Introduction: </strong>Glycyrrhetinic acids (GAs) are isolated from the <i>Glycyrrhiza glabra</i>. Interestingly, GAs and their synthetic derivatives have demonstrated numerous biological effects, including cytotoxic, antiviral, anti-inflammatory, and antimicrobial effects.</p><p><strong>Areas covered: </strong>The patents granted concerning natural and synthetic GAs are covered in this review (2018-2024). The most recent patented research on GA derivatives is outlined using the search terms 'glycyrrhetinic acid' on PubMed, SciFinder, and Google Patents.</p><p><strong>Expert opinion: </strong>Despite its biological effects, the further advancement and application of GA, particularly in clinical use, has been hindered by its limited druggability. This includes challenges such as low solubility and bioavailability. To enhance its biological activity and pharmaceutical efficacy, numerous research studies have focused on structural modifications, particularly to the C-3 (OH) and C-30 (CO<sub>2</sub>H) functional groups. The biological results of the C-30 amide derivatives demonstrate great potential. These modifications have produced numerous new GA derivatives with promising biological potential. The authors believe that chemists would be better off focusing their efforts on synthesizing heterocyclic analogues of GA, as this would enhance their biological activity and bioavailability. In addition, hybrid compounds of GA with other bioactive molecules could address issues of drug resistance and bioavailability.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1-19"},"PeriodicalIF":4.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Allosteric anticoagulation: emerging non-orthosteric inhibitors of factor XI and factor XIa.","authors":"Dmitrii V Kalinin","doi":"10.1080/13543776.2026.2759926","DOIUrl":"10.1080/13543776.2026.2759926","url":null,"abstract":"","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1-4"},"PeriodicalIF":4.7,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Santiago Torres, Diana Marcela Aragón Novoa, José Marcos Teixeira de Alencar Filho, Izabel Almeida Alves
{"title":"Global patent landscape of synthetic drugs for melasma (2015-2025): innovation trends, mechanistic shifts, and translational challenges.","authors":"Santiago Torres, Diana Marcela Aragón Novoa, José Marcos Teixeira de Alencar Filho, Izabel Almeida Alves","doi":"10.1080/13543776.2026.2726449","DOIUrl":"10.1080/13543776.2026.2726449","url":null,"abstract":"<p><strong>Introduction: </strong>Melasma is a chronic and highly recurrent hyperpigmentation disorder with substantial psychosocial burden and limited long-term therapeutic control. Because current treatments remain largely centered on conventional melanogenesis inhibition, a patent-based review is needed to clarify how synthetic drug innovation is evolving and whether emerging technologies address unmet therapeutic needs.</p><p><strong>Areas covered: </strong>This review analyzed global patent activity from 2015 to 2025 related to synthetic drugs for melasma. A structured search was conducted in the Espacenet database using the keyword 'melasma' and IPC code A61Q (cosmetic and dermatological preparations). After systematic screening, 17 patent filings were included. The analysis focused on geographic distribution, temporal trends, technological strategies, delivery systems, and mechanisms of action. Most patents (94.1%) were based on reformulation strategies, including novel delivery systems and combinations of existing compounds, while only one described a new chemical entity.</p><p><strong>Expert opinion: </strong>The current patent landscape reflects a predominance of incremental innovation, with limited exploration of disruptive strategies. Future advances will depend on targeting pathways beyond melanogenesis and overcoming key translational barriers, including delivery efficiency, safety, and scalability.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1029-1044"},"PeriodicalIF":4.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Aurora kinase inhibitors: an updated patent review (2021-present).","authors":"Yao-Sheng Zhang, Hong-Yu Zhang, Junmin Zhang, Shi-Wu Chen","doi":"10.1080/13543776.2026.2733162","DOIUrl":"10.1080/13543776.2026.2733162","url":null,"abstract":"<p><strong>Introduction: </strong>Aurora kinases are a family of serine/threonine kinases, responsible for regulating mitotic progression and their dysfunction is closely correlated with tumorigenesis. Since its discovery in the late 1990s, Aurora kinase has been established as a promising anti-tumor target.</p><p><strong>Areas covered: </strong>We have updated the clinical trial and patent information for Aurora kinase inhibitors from 2021 to the present, using PubMed, Web of Science, Espacenet Patent Search and www.clinicaltrials.gov for retrieval.</p><p><strong>Expert opinion: </strong>Selective Aurora kinase inhibitors, multi-target inhibitors or combination therapy currently represent the main development trends of Aurora kinase inhibitors. Improving pharmacokinetic properties, enhancing in <i>vivo</i> delivery efficiency and expanding the applications of Aurora kinase inhibitors beyond the antitumor field constitute the latest advances in the research of Aurora kinase inhibitors in recent years.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1011-1027"},"PeriodicalIF":4.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148962879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Progress with FAK inhibitors in the patent literature (2020-present).","authors":"Bing-Bing Chen, Rui-Peng Feng, Jin-Bo Niu, Jian Song, Yuan-Bo Cui, Sai-Yang Zhang","doi":"10.1080/13543776.2026.2735861","DOIUrl":"10.1080/13543776.2026.2735861","url":null,"abstract":"<p><strong>Introduction: </strong>Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that transduces signals from integrins, receptor tyrosine kinases, and growth factors to orchestrate cell adhesion, migration, and survival. Aberrant FAK hyperactivation promotes tumor proliferation, invasion, anti-apoptosis, and chemoresistance. Consequently, the recent U.S. FDA approval of the FAK inhibitor defactinib combined with avutometinib for recurrent KRAS-mutant low‑grade serous ovarian cancer (LGSOC) validates FAK as a clinically actionable anticancer target.</p><p><strong>Areas covered: </strong>This review discusses recent advances in FAK inhibitor development, focusing on small-molecule patents published from January 2020 to August 2026. A systematic search of SciFinder and WIPO databases was conducted for this period. It categorizes these novel inhibitors into several classes and summarizes their structural features, biological activities, design strategies, and structure-activity relationships (SAR).</p><p><strong>Expert opinion: </strong>Recent advances in FAK drug discovery have driven a transition from conventional kinase inhibition toward broader FAK pathway modulation, including improved inhibitors, dual-target strategies, and targeted protein degradation. The clinical success of defactinib-based combination therapy validates the therapeutic potential of FAK targeting, while emerging approaches offer opportunities to overcome resistance. Future progress will depend on biomarker-guided patient selection, rational combination regimens, and exploration of non-catalytic FAK functions to achieve more effective and durable therapies.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1045-1058"},"PeriodicalIF":4.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daowei Huang, Roujun Lu, Ruijing Tang, Jiarui Sun, Zhipei Sang
{"title":"Overcoming the blood-brain barrier for therapeutics targeting neurodegenerative diseases: a patent review (2020-present).","authors":"Daowei Huang, Roujun Lu, Ruijing Tang, Jiarui Sun, Zhipei Sang","doi":"10.1080/13543776.2026.2725660","DOIUrl":"10.1080/13543776.2026.2725660","url":null,"abstract":"<p><strong>Introduction: </strong>The blood-brain barrier (BBB) restricts drug entry into the CNS, with most therapeutics showing <1% brain penetration, limiting efficacy in neurodegenerative diseases.</p><p><strong>Areas covered: </strong>Patents (2020-2026) were retrieved from SciFinder, Web of Science, PubMed, and Reaxys using combinations of 'blood-brain barrier,' 'brain delivery,' and neurodegenerative disease terms. Technologies were included if supported by <i>in vitro</i> or <i>in vivo</i> BBB‑penetration evidence for neurodegenerative indications; purely computational, non‑English untranslated, and non‑targeted conventional formulation patents were excluded. Eligible patents were classified into protein/antibody‑based, small molecule, nanocarrier, physical‑assisted, permeability enhancer, and emerging technology categories.</p><p><strong>Expert opinion: </strong>Receptor-mediated transcytosis, dual-targeting ligands, and ultrasound opening are enhancing delivery precision; emerging systems (small molecules, peptides, nanozymes) combine penetration with target inhibition, overcoming traditional bottlenecks and accelerating clinical translation.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"993-1010"},"PeriodicalIF":4.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148826735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Positive allosteric modulators of AMPA receptors: advances and emerging trends.","authors":"Thomas Colson, Bernard Pirotte, Pierre Francotte","doi":"10.1080/13543776.2026.2748595","DOIUrl":"10.1080/13543776.2026.2748595","url":null,"abstract":"<p><strong>Introduction: </strong>AMPA receptors are key mediators of excitatory neurotransmission and attractive targets for central nervous system disorders. An updated review of AMPA receptor positive allosteric modulators is timely given recent medicinal chemistry advances and renewed translational interest.</p><p><strong>Areas covered: </strong>This review summarizes the evolution from early high-impact, seizure-prone ampakines to more refined low- to intermediate-impact modulators based on sulfur-containing heterocycles and sulfonamide scaffolds. We discuss the main structural and functional determinants of AMPA receptor pharmacology, including the dimer-interface allosteric site, flip/flop splice variants, and auxiliary proteins such as TARPs. Key chemotypes covered include benzamides, benzothiadiazines, benzoxathiazines such as TAK-653 and LT-102, constrained sulfonamides such as PF-04958242, PF-4778574 and MDI-222, and newer heterocyclic and bivalent ligands. Literature was selected through a focused review of published medicinal chemistry, pharmacology, and translational studies relevant to AMPA receptor PAMs.</p><p><strong>Expert opinion: </strong>AMPA receptor potentiation remains a promising strategy, but future candidates will need to combine potency, finely tuned efficacy, favorable pharmacokinetics, and circuit-level selectivity. The most successful next-generation PAMs will likely be those that maximize therapeutic window while minimizing seizure liability.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1-19"},"PeriodicalIF":4.7,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A patenting perspective of IKZF2 molecular glue degraders (2020-present).","authors":"Xuqing Zhang","doi":"10.1080/13543776.2026.2748593","DOIUrl":"10.1080/13543776.2026.2748593","url":null,"abstract":"<p><strong>Introduction: </strong>IKZF2 (Helios) maintains the suppressive function of regulatory T cells (Tregs) and is an emerging immuno-oncology target. Its degradation destabilizes Tregs, strengthens antitumor immunity, and may remodel the tumor microenvironment (TME) with reduced off-target toxicity. Recent patents focus on selective cereblon (CRBN)-recruiting molecular glues, combination therapies, and next-generation degraders.</p><p><strong>Areas covered: </strong>SciFinder and Google Patents were searched for IKZF2 molecular glue degraders reported in patents and peer-reviewed journals from January 2020 to September 2026.</p><p><strong>Expert opinion: </strong>The immunomodulatory drug (IMiD)-based degrader field is increasingly competitive, with growing emphasis on selectivity, alternative ligases, and artificial intelligence-enabled discovery. Because small structural changes can strongly affect ternary-complex formation and selectivity among IKZF proteins, structure-guided optimization remains essential. Dual degradation of IKZF2 and IKZF4 (Eos) may offer further opportunities, but programs must demonstrate differentiated biology, biomarker-guided patient selection, and clear clinical value.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1-24"},"PeriodicalIF":4.7,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}